Replies to post #225246 on Biotech Values

[flatlander_60048]

I believe that Fisher is a bit conflicted. They develop and market MDx equipment and consumables yet they also run a major online catalog exchange that features the equipment of competitors.

https://www.fishersci.com/us/en/catalog/search/products?sortBy=popularity&keyword=Automated+Molecular+Diagnostics+System+Instruments&searchType=P

I used to use the Fisher relative popularity feature to track Biocartis' sales of Idylla systems. However, BCART launched their own sales force in the US so Fisher is no longer the only sales outlet.

In any event liquid biopsy is becoming more crowded that than many investors in the field realize.

FL

[swampboots]

Liquid biopsy terminology is a marketing branding tactic to add inventive breakthrough "umph" to a category which is simply investigating new blood tests to locate better probable markers or gene expressions which may statistically iomprove the tools to the investigatory quest for earlier probable diagnosis and individual treatment platforms.
Already for example, a biomarker test may replace the PSA test for early detection of prostate cancer, but expensive ($500) and still early in exemplary performance. But if it gains traction it will probably be called a "liquid biopsy" to short cut its explanation to patients already familiar with the more invasive term biopsy.